Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
about
Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient SensorsA novel, long-acting glucagon-like peptide receptor-agonist: dulaglutideUsing real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.Incretin-based therapies in prediabetes: Current evidence and future perspectivesThe risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort studyDipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study.Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort StudyAlpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysisA real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.An update on DPP-4 inhibitors in the management of type 2 diabetes.Pancreas Volume and Fat Deposition in Diabetes and Normal Physiology: Consideration of the Interplay Between Endocrine and Exocrine PancreasUse of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan.[Benefits of large healthcare databases for drug risk research].Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.[Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?]Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
P2860
Q26770832-FE03F78F-5578-4A5B-B0AA-19376F570846Q26796417-42CF266E-5361-4DE8-B31F-3F9ABB86713BQ30848457-F3451756-376A-40B9-B508-7827E04CA3DEQ31066859-8298575A-9BAD-40F5-A381-87BEE3F981A2Q31167862-C479C79E-A11D-4920-86D4-051C078B8A11Q34558740-70DB546E-82E4-44DB-B11D-593D39782A76Q34559981-1FB1082D-247F-42B3-839A-DE7FCD68E6F6Q34699191-350BD58D-50DF-40A5-B429-B102D163466AQ36064999-81D1B8C6-B4D6-402D-B941-3304A9EF948EQ37176363-C0015220-293D-4FA4-BA35-D3138114D428Q37206067-622F9C42-450D-49B6-B4C9-1B43A73EB5B6Q37232678-88823777-DADE-4E69-AFC0-93DDF3954BFDQ37696559-22F4FC0D-0249-4BEF-9E46-FD09BD2F1E65Q38255715-63BF8542-A04B-4E14-8826-10AAC07FF1B9Q38258278-2AB6A6B0-8B6E-4386-B5DE-AC0B1839549FQ38335751-47520D19-EF5D-498D-B112-C4B16FAB36AFQ38412153-AE931B57-15CE-43F3-B767-883B3F1A0B2BQ38442816-D248414A-A6B2-4EBB-A433-88BD4CB9AB09Q38997456-A491668C-4F54-4AB3-81C7-1F122483E0E4Q39052404-72FB7E9E-55EB-42BA-A48E-DD978208CC3DQ39156623-D5BED8C1-94FC-47D3-9440-DA4C7D96BF33Q40478079-6EBBCFF1-7A51-4244-87C3-FDB382EDBE0AQ41656205-31F35784-5C99-4875-8142-A919ECD4ACB5Q47386188-A6408FCF-842E-4755-B3BA-8A7C286707DDQ48007843-2C9E8051-0698-432E-95E0-8395598B75EDQ51262448-F21521C2-9A66-4434-896D-15F401E5C1B5Q55086466-0DB9FC66-C857-428A-9E12-66B702055A05Q57477167-8747A723-579A-4733-BA44-882E317A6A52
P2860
Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incretin based drugs and risk ...... type 2 diabetes: cohort study.
@en
Incretin based drugs and risk ...... type 2 diabetes: cohort study.
@nl
type
label
Incretin based drugs and risk ...... type 2 diabetes: cohort study.
@en
Incretin based drugs and risk ...... type 2 diabetes: cohort study.
@nl
prefLabel
Incretin based drugs and risk ...... type 2 diabetes: cohort study.
@en
Incretin based drugs and risk ...... type 2 diabetes: cohort study.
@nl
P2093
P2860
P356
P1433
P1476
Incretin based drugs and risk ...... type 2 diabetes: cohort study.
@en
P2093
Dominique Hillaire-Buys
Jean-Luc Faillie
Laurent Azoulay
Samy Suissa
Valerie Patenaude
P2860
P356
10.1136/BMJ.G2780
P407
P577
2014-04-24T00:00:00Z